Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Zoulim, Fabien | en_US |
dc.contributor.author | Locarnini, Stephen | en_US |
dc.contributor.author | Bartholomeusz, Angeline | en_US |
dc.contributor.author | Ghany, Marc G. | en_US |
dc.contributor.author | Pawlotsky, Jean-Michel | en_US |
dc.contributor.author | Liaw, Yun-Fan | en_US |
dc.contributor.author | Mizokami, Masashi | en_US |
dc.contributor.author | Kuiken, Carla | en_US |
dc.date.accessioned | 2007-09-20T18:44:27Z | |
dc.date.available | 2008-09-08T14:25:12Z | en_US |
dc.date.issued | 2007-07 | en_US |
dc.identifier.citation | Lok, Anna S.; Zoulim, Fabien; Locarnini, Stephen; Bartholomeusz, Angeline; Ghany, Marc G.; Pawlotsky, Jean-Michel; Liaw, Yun-Fan; Mizokami, Masashi; Kuiken, Carla (2007)."Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management Potential conflict of interest: Dr. Lok receives research support and serves on advisory board of GlaxoSmithKline, Gilead, Bristol Myers Squibb, Idenix, Roche Molecular Diagnostics and Innogenetics. Dr. Zoulim serves on advisory board of Gilead, Idenix, Bristol Myers Squibb, Innogenetics and receives research support from bioMerieux. Dr. Locarnini receives research support and serves on advisory board of Gilead Sciences, Bristol-Myers Squibb, Pharmasset, LG Sciences, Innogenetics and Evivar Pty Ltd. Dr. Bartholomeusz is a Consultant to Evivar Medical Pty Ltd. Dr. Pawlotsky receives research support and/or serves on advisory board of GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Idenix and Novartis. Dr. Liaw receives research support and serves on advisory board and speaker bureau of Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Idenix. ." Hepatology 46(1): 254-265. <http://hdl.handle.net/2027.42/56065> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/56065 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17596850&dopt=citation | en_US |
dc.description.abstract | Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. (H EPATOLOGY 2007;46:254–265.) | en_US |
dc.format.extent | 239679 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI ; fax: 734-936-7392 ; Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362 | en_US |
dc.contributor.affiliationother | INSERM, U271; UniversitÉ Lyon I; Hospices Civils de Lyon, Lyon, France | en_US |
dc.contributor.affiliationother | Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia | en_US |
dc.contributor.affiliationother | Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia | en_US |
dc.contributor.affiliationother | Liver Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U841, Hopital Henri Mondor, Universite Paris 12, Creteil, France | en_US |
dc.contributor.affiliationother | Liver Research Unit, Chang Gung University and Memorial Hospital, Taipei, Taiwan | en_US |
dc.contributor.affiliationother | Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan | en_US |
dc.contributor.affiliationother | Theoretical Biology and Biophysics Group (T-10), Los Alamos National Laboratory, Los Alamos, NM | en_US |
dc.identifier.pmid | 17596850 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/56065/1/21698_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/hep.21698 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.